Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:PRAX News 16 October 2025 - 14 January 2026

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom

Shares of Praxis Precision Medicines rose about 8% to $303.23 by mid-afternoon Wednesday after the company named epilepsy specialist Dr. Orrin Devinsky as head of clinical strategy. Investors are watching two FDA drug applications set for mid-February. Praxis recently raised $575 million in a public offering. The broader biotech sector outperformed the market, while major indexes fell.
14 January 2026
·
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines stock jumps after FDA Breakthrough Therapy tag for tremor drug, BTIG lifts target

Praxis Precision Medicines shares jumped 13.25% to $304.58 Monday after the FDA granted Breakthrough Therapy Designation to ulixacaltamide for essential tremor. The company plans to file a New Drug Application in early 2026. BTIG raised its price target on PRAX to $843 from $507. The stock slipped about 1% in after-hours trading.
30 December 2025
···
Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines (PRAX) stock jumps 13% after FDA breakthrough designation for tremor drug

Praxis Precision Medicines shares jumped 13% to $304.58 after the FDA granted Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The stock traded between $318.08 and $275.00 during the session. Praxis said it plans to file a New Drug Application in early 2026. Analyst BTIG raised its price target on Praxis to $843.
30 December 2025
··
Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines (PRAX) Soars on FDA Momentum and 760-Dollar Target: December 9, 2025 Stock Deep Dive

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has turned into one of 2025’s most dramatic biotech stories. On December 9, 2025, the stock is trading around $265–270 per share, near its 52‑week high of about $278 and far above its low near $26.70, giving the company a market capitalization of roughly $6.6 billion.StockAnalysis+1 Behind that move is a mix of powerful late‑stage clinical data, accelerating FDA interactions, increasingly aggressive analyst targets — including a new $760 price target from Guggenheim — and a growing cloud of controversy after a short‑seller attack on Praxis’s lead program.Quiver Quantitative+2Investing.com+2 Here is a detailed, news-style
9 December 2025
·
Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines (PRAX) Stock Soars After Epilepsy Breakthrough and FDA Pre‑NDA Win

Praxis Precision Medicines, Inc. (NASDAQ: PRAX) ripped higher again on 5 December 2025, extending one of the most dramatic biotech rallies of the year after positive epilepsy data and a favorable pre‑NDA meeting with the FDA. By the closing bell on Friday, PRAX finished at $247.99, up 30.5% on the day, with a new 52‑week range of $26.70–$277.44 and a market capitalization around $6.2 billion. StockAnalysis+1 Below is a deep dive into the latest news, forecasts, and analysis as of 5 December 2025, and what they may mean for investors watching PRAX stock. Key Takeaways PRAX Stock Today: A Volatile
6 December 2025
·
Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

Biggest Stock Gainers Today (December 5, 2025): TGL, SMX, WHLR, DBRG, TORO, PRAX and RBRK Lead a Volatile Session

The U.S. stock market logged another upbeat session on Friday, December 5, 2025, with the S&P 500, Nasdaq 100 and Dow all edging higher. But beneath the index-level moves, a cluster of highly volatile small caps, high‑growth tech names and a few mid‑caps stole the show with spectacular double‑ and even triple‑digit gains. StockAnalysis+1 Below is a breakdown of the biggest stock gainers today, why they moved, and what recent forecasts and analyst commentary suggest about their outlooks. All data and price moves refer to the U.S. session on December 5, 2025, unless otherwise noted. Top 10 Biggest U.S. Stock Gainers Today (By
6 December 2025
············
Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Praxis Precision Medicines (PRAX) Stock Surges on FDA Progress and Epilepsy Trial Wins: Latest News and 2026 Forecast

Updated December 5, 2025 – all developments since December 4, 2025 Praxis Precision Medicines, Inc. (NASDAQ: PRAX) has moved back into the market spotlight after a flurry of major announcements on December 4, 2025. The biotech’s stock — already one of 2025’s wildest movers — is reacting to fresh positive data in rare epilepsies and new regulatory momentum for its lead essential tremor drug. Below is a structured rundown of what has happened since December 4, 2025, how analysts now value PRAX stock, and what investors are watching into 2026. This article is for information only and is not financial
5 December 2025
·
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Market Outlook With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026 (e.g. vormatrigine POWER1 topline, PRAX-562 EMBOLD readoutnasdaq.comneurologylive.com). Management’s guidance (via press releases and presentations) has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechsnasdaq.com. In the near term, analysts will scrutinize FDA feedback and
16 October 2025
··

Stock Market Today

China Construction Bank Class A stock ticks up at Friday close as China data looms

China Construction Bank Class A stock ticks up at Friday close as China data looms

7 February 2026
SHANGHAI, Feb 8, 2026, 04:34 GMT+8 — Market closed China Construction Bank’s Class A shares ended Friday a touch higher in Shanghai, closing up 0.11% at 8.84 yuan. With mainland markets shut for the weekend, traders are already looking at next week’s inflation and credit numbers for direction. The big state lender is a bellwether for China’s financial system and a heavyweight in benchmark indices, so small moves often signal positioning around policy and economic data rather than company headlines. The next few sessions bring January inflation and lending readings that can swing expectations for interest rates and bank earnings
PetroChina Class A stock rises with oil rebound — what 601857 traders watch next week

PetroChina Class A stock rises with oil rebound — what 601857 traders watch next week

7 February 2026
PetroChina A-shares rose 2.3% to 10.77 yuan Friday, outperforming the Shanghai Composite, which fell 0.25%. Crude prices rebounded, with Brent settling at $68.05 a barrel, as traders tracked U.S.-Iran talks and new EU sanctions proposals. About 198.5 million PetroChina shares traded in the session. Investors await the company’s next earnings report later this quarter.
Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

Morgan Stanley stock price bounces after three-day slide; what to watch before Monday

7 February 2026
Morgan Stanley shares rose 2.34% to $179.96 Friday, snapping a three-day slide as the Dow closed above 50,000 for the first time. About 9.1 million MS shares traded hands. The rebound followed Thursday’s 2.35% drop and came amid renewed rate-cut speculation and surging AI spending. Morgan Stanley remains 6.6% below its January high.
Go toTop